Company Analysis
Sign in

Sutro Biopharma, Inc. (STRO)

Nasdaq: STRO · Biological Products, (No Diagnostic Substances) · South San Francisco, CA · filing with the SEC since 2006
Full chart Alerts Compare
Grade4.8
◀ Past 4.2● Present 4.7▶ Future 5.7
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

52 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Sutro Biopharma, Inc.’s names, not what it holds today.

Patents granted
52
52 utility, 1976 to Dec 31, 2025
Granted in 2025
7
Against 6 in 2024 and 3 in 2023
Applications published
100
10 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'10'11'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology13
Pharmaceuticals9
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
SUTRO BIOPHARMA, INC. its own name
named as the applicant on its applications, in US
0 granted
90 published
Sutro Biopharma, Inc. its own name
US, as the owner printed on each patent
52 granted
10 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 30, 202512,427,201Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugatesPharmaceuticalsSutro Biopharma, Inc.
Sep 9, 202512,410,393E. coli strains having an oxidative cytoplasmBiotechnologySutro Biopharma, Inc.
Aug 26, 202512,398,197Antibodies with engineered CH2 domains, compositions thereof and methods of using the sameBiotechnologySutro Biopharma, Inc.
Jul 8, 202512,351,850Methods of producing full-length antibodies using E. coliBiotechnologySutro Biopharma, Inc.
Apr 8, 202512,269,801Modified amino acidsOrganic fine chemistrySutro Biopharma, Inc.
Mar 18, 202512,252,552Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their usePharmaceuticalsSutro Biopharma, Inc.
Feb 18, 202512,226,490Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary classPharmaceuticalsSutro Biopharma, Inc.
Nov 19, 202412,144,869Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugatesPharmaceuticalsSutro Biopharma, Inc.
Sep 24, 202412,098,406Formulations for drying bacterial cell extractsBiotechnologySutro Biopharma, Inc.
Aug 27, 202412,071,477Anti-folate receptor alpha antibody conjugated with hemiasterlinsPharmaceuticalsSutro Biopharma, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0361253STING AGONIST COMPOUNDSOrganic fine chemistrySUTRO BIOPHARMA, INC.
Nov 13, 20252025/0346650ANTIBODIES WITH ENGINEERED CH2 DOMAINS, COMPOSITIONS THEREOF AND METHODS OF USING THE SAMEBiotechnologySUTRO BIOPHARMA, INC.
Oct 2, 20252025/0304723MODIFIED FC PROTEINS COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES OF THE SAME, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USEPharmaceuticalsSUTRO BIOPHARMA, INC.
Jul 24, 20252025/0236674ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATESPharmaceuticalsSUTRO BIOPHARMA, INC.
Jul 24, 20252025/0236594MODIFIED AMINO ACIDSOrganic fine chemistrySUTRO BIOPHARMA, INC.
Apr 17, 20252025/0122306ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-TISSUE FACTOR ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-TISSUE FACTOR ANTIBODIES AND ANTIBODY CONJUGATESPharmaceuticalsSUTRO BIOPHARMA, INC.
Apr 3, 20252025/0108048STING AGONIST COMPOUNDS AND CONJUGATESPharmaceuticalsSUTRO BIOPHARMA, INC.
Mar 20, 20252025/0090676ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATES AND THEIR USESPharmaceuticalsSUTRO BIOPHARMA, INC.
Jan 16, 20252025/0018054ANTI-ROR1 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI ROR1 ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODY CONJUGATESPharmaceuticalsSUTRO BIOPHARMA, INC.
Jan 2, 20252025/0002604ANTIBODIES COMPRISING SITE-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, METHODS OF THEIR PREPARATION AND METHODS OF THEIR USEBiotechnologySUTRO BIOPHARMA, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 16 · Biotechnology 7 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton STRO · research, not advice